Dr. Plimack on Frontline Checkpoint Inhibitors in Bladder Cancer

Elizabeth Plimack, MD
Published: Wednesday, Nov 29, 2017



Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses checkpoint inhibitors in the frontline setting of bladder cancer.

There are currently 2 approved checkpoint inhibitors for the first-line treatment of patients with metastatic bladder cancer who are cisplatin ineligible—pembrolizumab (Keytruda) and atezolizumab (Tecentriq).

The results with either of these agents can be durable in this patient population, says Plimack, but there is currently no long-term follow-up data available.
 


Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses checkpoint inhibitors in the frontline setting of bladder cancer.

There are currently 2 approved checkpoint inhibitors for the first-line treatment of patients with metastatic bladder cancer who are cisplatin ineligible—pembrolizumab (Keytruda) and atezolizumab (Tecentriq).

The results with either of these agents can be durable in this patient population, says Plimack, but there is currently no long-term follow-up data available.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x